Gilead Sciences (TICKER: GILD) Benchmark And Performance Data

there are 10 of samples in the benchmark for Gilead Sciences in year 2022 in 2022. The total inventory for Gilead Sciences was $922,000,000.00 in 2019. The total inventory for Gilead Sciences was $814,000,000.00 in 2018. The total inventory for Gilead Sciences was $801,000,000.00 in 2017. The total inventory for Gilead Sciences was $1,955,000,000.00 in 2015. The total inventory for Gilead Sciences was $1,744,982,000.00 in 2012. The total inventory for Gilead Sciences was $1,697,000,000.00 in 2013. The total inventory for Gilead Sciences was $1,683,000,000.00 in 2020. The total inventory for Gilead Sciences was $1,618,000,000.00 in 2021. The total inventory for Gilead Sciences was $1,587,000,000.00 in 2016. The total inventory for Gilead Sciences was $1,386,000,000.00 in 2014. The sales, general, and administrative (SGA) for Gilead Sciences was $5,246,000,000.00 in 2021. The sales, general, and administrative (SGA) for Gilead Sciences was $5,151,000,000.00 in 2020. The sales, general, and administrative (SGA) for Gilead Sciences was $4,381,000,000.00 in 2019. The sales, general, and administrative (SGA) for Gilead Sciences was $4,056,000,000.00 in 2018. The sales, general, and administrative (SGA) for Gilead Sciences was $3,878,000,000.00 in 2017. The sales, general, and administrative (SGA) for Gilead Sciences was $3,426,000,000.00 in 2015. The sales, general, and administrative (SGA) for Gilead Sciences was $3,398,000,000.00 in 2016. The sales, general, and administrative (SGA) for Gilead Sciences was $2,983,000,000.00 in 2014. The sales, general, and administrative (SGA) for Gilead Sciences was $1,699,000,000.00 in 2013. The sales, general, and administrative (SGA) for Gilead Sciences was $1,461,000,000.00 in 2012. The sales, general, and administrative (SGA) for Gilead Sciences was $$5,673,000,000 in 2022. The revenue volatility for Gilead Sciences was 9.05% in 2022. The market capitalization for Gilead Sciences was $96,106,290,000.00 in 2020. The market capitalization for Gilead Sciences was $93,376,315,613.00 in 2021. The market capitalization for Gilead Sciences was $91,052,940,000.00 in 2014. The market capitalization for Gilead Sciences was $87,661,750,000.00 in 2013. The market capitalization for Gilead Sciences was $86,350,440,000.00 in 2012. The market capitalization for Gilead Sciences was $77,509,740,000.00 in 2016. The market capitalization for Gilead Sciences was $77,359,260,000.00 in 2017. The market capitalization for Gilead Sciences was $74,609,750,000.00 in 2015. The market capitalization for Gilead Sciences was $107,676,834,093.00 in 2018. The market capitalization for Gilead Sciences was $103,546,560,000.00 in 2019. The market capitalization for Gilead Sciences was $$95,895,000,000 in 2022. The gross revenue for Gilead Sciences was $9,702,000,000.00 in 2012. The gross revenue for Gilead Sciences was $32,639,000,000.00 in 2015. The gross revenue for Gilead Sciences was $30,390,000,000.00 in 2016. The gross revenue for Gilead Sciences was $27,305,000,000.00 in 2021. The gross revenue for Gilead Sciences was $26,107,000,000.00 in 2017. The gross revenue for Gilead Sciences was $24,890,000,000.00 in 2014. The gross revenue for Gilead Sciences was $24,689,000,000.00 in 2020. The gross revenue for Gilead Sciences was $22,449,000,000.00 in 2019. The gross revenue for Gilead Sciences was $22,127,000,000.00 in 2018. The gross revenue for Gilead Sciences was $11,202,000,000.00 in 2013. The gross revenue for Gilead Sciences was $$27,281,000,000 in 2022. The gross margin for Gilead Sciences was $40.23% in 2022. The days sales outstanding for Gilead Sciences was 62 days in 2022. The days payable outstanding for Gilead Sciences was 52 days in 2022. The days of inventory for Gilead Sciences was $101 in 2022. The cost of goods sold (COGS) for Gilead Sciences was 20.74% in 2022. The cost of goods sold (COGS) for Gilead Sciences was $6,601,000,000.00 in 2021. The cost of goods sold (COGS) for Gilead Sciences was $4,853,000,000.00 in 2018. The cost of goods sold (COGS) for Gilead Sciences was $4,675,000,000.00 in 2019. The cost of goods sold (COGS) for Gilead Sciences was $4,572,000,000.00 in 2020. The cost of goods sold (COGS) for Gilead Sciences was $4,371,000,000.00 in 2017. The cost of goods sold (COGS) for Gilead Sciences was $4,261,000,000.00 in 2016. The cost of goods sold (COGS) for Gilead Sciences was $4,006,000,000.00 in 2015. The cost of goods sold (COGS) for Gilead Sciences was $3,788,000,000.00 in 2014. The cost of goods sold (COGS) for Gilead Sciences was $2,859,000,000.00 in 2013. The cost of goods sold (COGS) for Gilead Sciences was $2,471,000,000.00 in 2012. The cost of goods sold (COGS) for Gilead Sciences was $$5,657,000,000 in 2022. The cash to cash cycle time for Gilead Sciences was 111 in 2022. The annual percentage growth rate of Gilead Sciences was 0.00% in 2022. Gilead Sciences in its benchmark peer group, had rank 7 for gross revenue in 2022. Gilead Sciences in its benchmark peer group, had rank 7 for cash to cash cycle time in 2022. Gilead Sciences in its benchmark peer group, had rank 4 for sales growth in 2022. Gilead Sciences in its benchmark peer group, had rank 4 days for days sales outstanding in 2022. Gilead Sciences in its benchmark peer group, had rank 4 days for days of inventory in 2022. Gilead Sciences in its benchmark peer group, had rank 1 for cost of goods sold as a percent of revenue in 2022. Gilead Sciences headquarters region is West. Gilead Sciences has ticker symbol GILD. Gilead Sciences has the following profile: Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.. Gilead Sciences has primary indstury Drug Manufacturers - General. Gilead Sciences had a $$10,069,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. Gilead Sciences had Organon, and Eli Lilly, and AbbVie, and Pfizer, and Bristol-Myers Squibb, and Amgen, and Gilead Sciences, and Biogen, and Johnson & Johnson, and Merck benchmark peer companies for its SIC code in 2022. Gilead Sciences had 6 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. Gilead Sciences had 28 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. Gilead Sciences had 22 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. Gilead Sciences had 2.32% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. Gilead Sciences had 17,000 number of employees in 2022. Gilead Sciences had 0.00% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. Gilead Sciences had 0.00% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. Gilead Sciences had 0.00% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. Gilead Sciences can reduce overall cost by $$359,000,000 by improving both COGS and SGA to next benchmark tier in 2022. Gilead Sciences can reduce inventory with practices including SKU Reduction in 2022. Gilead Sciences can reduce inventory with practices including Reduce Manufacturing Latency in 2022. Gilead Sciences can reduce inventory with practices including Forecast Accuracy in 2022. Gilead Sciences can reduce inventory with practices including Demand Shaping in 2022. Gilead Sciences can reduce days sales outstanding with practices including in 2022. Gilead Sciences can increase sales revenue by $$10,069,000,000 improving sales performance to next benchmark tier in 2022. Gilead Sciences can increase revenue growth by $$0 by improving growth performance to next benchmark tier in 2022. Gilead Sciences can increase overall revenue by $$10,070,000,000 by improving both growth and sales performance to next benchmark tier in 2022. Gilead Sciences can increase days payables outstanding with practices including Strategic Sourcing in 2022. Gilead Sciences can increase days payables outstanding by $2,840,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. Gilead Sciences can improve total financial performance by $$15,339,000,000 by improving revenue, costs, and working capital in 2022. Gilead Sciences can decrease overall working capital by $$4,911,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. Gilead Sciences can decrease inventory days by $1,644,000,000 days by reducing inventory days to next benchmark tier in 2022. Gilead Sciences can decrease days sales outstanding by $426,000,000 days by reducing days sales outstanding to next benchmark tier in 2022. Gilead Sciences can accelerate revenue growth practices including Revenue-optimized Planning in 2022. Gilead Sciences can accelerate revenue growth practices including Pricing Optimization in 2022. Gilead Sciences can accelerate revenue growth practices including Accelerate Design Pipeline in 2022. 82 days was the measured parity or middle performance level for cash to cash cycle time in Gilead Sciences's peer group in 2022. 79 days was the measured superior or top ten performance level for days of inventory in Gilead Sciences's peer group in 2022. 68 days was the measured advantage or top third performance level for cash to cash cycle time in Gilead Sciences's peer group in 2022. 66 days was the measured parity or middle performance level for days sales outstanding in Gilead Sciences's peer group in 2022. 61 days was the measured advantage or top third performance level for days sales outstanding in Gilead Sciences's peer group in 2022. 6.73% was the measured superior or top ten performance level for sales volatility in Gilead Sciences's peer group in 2022. 56 days was the measured superior or top ten performance level for days sales outstanding in Gilead Sciences's peer group in 2022. 37.46% was the measured superior or top ten performance level for gross margin in Gilead Sciences's peer group in 2022. 37 days was the measured superior or top ten performance level for cash to cash cycle time in Gilead Sciences's peer group in 2022. 26.85% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in Gilead Sciences's peer group in 2022. 22.98% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in Gilead Sciences's peer group in 2022. 21.84% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in Gilead Sciences's peer group in 2022. 14.35% was the measured parity or middle performance level for sales volatility in Gilead Sciences's peer group in 2022. 129 days was the measured parity or middle performance level for days of inventory in Gilead Sciences's peer group in 2022. 100 days was the measured advantage or top third performance level for days of inventory in Gilead Sciences's peer group in 2022. 10.93% was the measured advantage or top third performance level for sales volatility in Gilead Sciences's peer group in 2022. 0.03% was the measured superior or top ten performance level for sales growth in Gilead Sciences's peer group in 2022. 0.00% was the measured advantage or top third performance level for sales growth in Gilead Sciences's peer group in 2022. -0.01% was the measured parity or middle performance level for sales growth in Gilead Sciences's peer group in 2022. $33.59% was the measured advantage or top third performance level for gross margin in Gilead Sciences's peer group in 2022. $30.58% was the measured parity or middle performance level for gross margin in Gilead Sciences's peer group in 2022. $$95,482,000,000 was the measured superior or top ten performance level for gross revenue in Gilead Sciences's peer group in 2022. $$58,423,000,000 was the measured advantage or top third performance level for gross revenue in Gilead Sciences's peer group. $$37,350,000,000 was the measured parity or middle performance level for gross revenue in Gilead Sciences's peer group in 2022.